KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Operating Expenses (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Other Operating Expenses data on record, last reported at $10.0 million in Q3 2025.

  • For Q3 2025, Other Operating Expenses rose 225.0% year-over-year to $10.0 million; the TTM value through Dec 2025 reached $10.0 million, up 118.73%, while the annual FY2025 figure was $10.0 million, 118.73% up from the prior year.
  • Other Operating Expenses reached $10.0 million in Q3 2025 per REGN's latest filing, up from -$15.5 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $1.8 billion in Q2 2021 and bottomed at -$42.0 million in Q3 2021.
  • Average Other Operating Expenses over 5 years is $114.9 million, with a median of $550000.0 recorded in 2023.
  • Peak YoY movement for Other Operating Expenses: soared 3468.33% in 2021, then plummeted 3200.0% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at -$42.0 million in 2021, then surged by 115.71% to $6.6 million in 2022, then tumbled by 92.42% to $500000.0 in 2023, then tumbled by 3200.0% to -$15.5 million in 2024, then soared by 164.52% to $10.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $10.0 million in Q3 2025, -$15.5 million in Q4 2024, and -$8.0 million in Q3 2024.